Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...
View Lixte Biotechnology Holdings, Inc. LIXT stock quote prices, financial information, real-time forecasts, and company news from CNN.
Tetra Pak and Lund University launch Biotech Heights, a hub for food and material biotechnology, enabling start-ups and researchers to collaborate on sustainable solutions.
LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended ...
1.1a Congress must establish a National Biotechnology Coordination Office (NBCO) within the Executive Office of the President with a director, appointed by the President, who would coordinate ...
Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but ...
StockStory.org on MSN
A look back at biotechnology stocks’ Q4 earnings: Incyte (NASDAQ:INCY) vs. the rest of the pack
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...
Plant Biotechnology is a critical field at the intersection of sustainable agriculture, environmental management, and industrial innovation. Despite the ...
The longevity biotechnology industry is rapidly evolving with the amount of academic funding and venture investment increasing at the exponential pace. Over thirty longevity startups and approximately ...
Do you want to be at the forefront of the rapidly growing biotechnology field? Do you want to develop products derived from living organisms and biomolecules? Do you have a passion for biochemistry, ...
The average one-year price target for Nautilus Biotechnology (NasdaqCM:NAUT) has been revised to $4.08 / share. This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results